SXTC VS VYNT Stock Comparison

Performance

SXTC
10/100

SXTC returned -87.22% in the last 12 months. Based on SPY's performance of -11.50%, its performance is below average giving it a score of 10 of 100.

VYNT
10/100

VYNT returned -92.37% in the last 12 months. Based on the other stocks in its sector with an average return of -3.19%, its performance is below average giving it a grade of 10 of 100.

Technicals

SXTC
21/100

SXTC receives a 21 of 100 based on 14 indicators. 2 are bullish, 10 are bearish.

VYNT
10/100

VYNT receives a 10 of 100 based on 14 indicators. 0 are bullish, 12 are bearish.

Profit

SXTC
63/100

Out of the last 8 quarters, SXTC has had 7 profitable quarters and has increased their profits year over year on 2 of them.

VYNT
26/100

Out of the last 17 quarters, VYNT has had 4 profitable quarters and has increased their profits year over year on 3 of them.

Volatility

SXTC
40/100

SXTC has had a lower than average amount of volatility over the last 12 months giving it a score of 40 of 100.

VYNT
31/100

VYNT has had a lower than average amount of volatility over the last 12 months giving it a grade of 31 of 100.

Earnings

SXTC

"Earnings" not found for SXTC

VYNT
47/100

VYNT has missed earnings 2 times in the last 20 quarters.

All score calculations are broken down here to help you make more informed investing decisions

China SXT Pharmaceuticals, Inc. Ordinary Shares Summary

Nasdaq / SXTC

Healthcare

Drug Manufacturers - Specialty & Generic

China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine piece tablets (TCMP) in China. The company offers advanced, fine, and regular TCMP products, such as ChenXiang, SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. As of March 31, 2022, it had an end-customer base of 68 pharmaceutical companies, 14 chain pharmacies, and 20 hospitals in 10 provinces and municipalities in China. The company was founded in 2005 and is headquartered in Taizhou, China.

Vyant Bio, Inc. Common Stock Summary

Nasdaq / VYNT

Healthcare

Biotechnology

Vyant Bio, Inc., a biotechnology company, discovers drugs for complex neurodevelopmental and neurodegenerative disorders. The company's central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. It focuses on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome (Rett), CDKL5 deficiency disorders (CDD,) and familial Parkinson's disease (PD). Vyant Bio, Inc. has a collaboration agreement to discover drugs for the treatment of Parkinson's Disease. The company is based in Cherry Hill, New Jersey.

Power up your portfolio